Los Angeles Capital Management & Equity Research Inc. Increases Holdings in Amgen, Inc. (AMGN)

Los Angeles Capital Management & Equity Research Inc. lifted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 60.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 558,051 shares of the medical research company’s stock after purchasing an additional 210,056 shares during the period. Amgen accounts for about 0.7% of Los Angeles Capital Management & Equity Research Inc.’s portfolio, making the stock its 27th largest position. Los Angeles Capital Management & Equity Research Inc. owned 0.09% of Amgen worth $108,636,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Ruggie Capital Group grew its stake in Amgen by 297.1% in the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 101 shares in the last quarter. Arlington Partners LLC lifted its holdings in Amgen by 86.7% during the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after purchasing an additional 65 shares during the last quarter. Massey Quick Simon & CO. LLC lifted its holdings in Amgen by 710.5% during the 4th quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock worth $30,000 after purchasing an additional 135 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in Amgen during the 4th quarter worth approximately $39,000. Finally, Prime Capital Investment Advisors LLC acquired a new stake in Amgen during the 4th quarter worth approximately $42,000. Institutional investors own 79.18% of the company’s stock.

Shares of Amgen stock traded down $5.00 on Friday, hitting $177.47. The company had a trading volume of 8,266,592 shares, compared to its average volume of 2,669,918. The company has a market cap of $109.31 billion, a PE ratio of 12.32, a price-to-earnings-growth ratio of 2.17 and a beta of 1.21. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36. Amgen, Inc. has a 1 year low of $165.22 and a 1 year high of $210.19.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.26 by $0.16. Amgen had a return on equity of 66.74% and a net margin of 35.35%. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $5.88 billion. During the same period in the prior year, the company posted $2.89 earnings per share. As a group, research analysts anticipate that Amgen, Inc. will post 13.96 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 40.28%.

In other news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total value of $386,360.00. Following the completion of the transaction, the director now directly owns 15,092 shares of the company’s stock, valued at $2,915,472.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 6,000 shares of company stock valued at $1,144,120 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Several brokerages have weighed in on AMGN. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. Goldman Sachs Group reissued a “buy” rating and set a $232.00 price target on shares of Amgen in a report on Thursday, January 17th. Oppenheimer set a $224.00 price target on Amgen and gave the stock a “buy” rating in a report on Sunday, January 27th. Royal Bank of Canada reissued a “neutral” rating and set a price target on shares of Amgen in a report on Monday, January 14th. Finally, Citigroup boosted their price objective on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research report on Friday, January 4th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Amgen presently has a consensus rating of “Hold” and a consensus price target of $209.11.

COPYRIGHT VIOLATION WARNING: “Los Angeles Capital Management & Equity Research Inc. Increases Holdings in Amgen, Inc. (AMGN)” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/amgen-inc-amgn-position-increased-by-los-angeles-capital-management-equity-research-inc.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Further Reading: Coverage Ratio

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.